| 前收盘价格 | 73.64 |
| 成交量 | 4,758,318 |
| 预期市盈率 (P/E Forward) | 18.36 |
| 价格/销量 (P/S) | 3.30 |
| 股市价格/股市净资产 (P/B) | 1.64 |
| 52周波幅 | |
| 股息率 (DY TTM) | 0.49% |
| 营业毛利率 | 11.28% |
| 营业利益率 (TTM) | 13.30% |
| 稀释每股收益 (EPS TTM) | 2.25 |
| 季度收入增长率 (YOY) | 0.60% |
| 季度盈利增长率 (YOY) | 41.10% |
| 总债务/股东权益 (D/E MRQ) | 23.63% |
| 流动比率 (MRQ) | 2.70 |
| 营业现金流 (OCF TTM) | 2.12 B |
| 杠杆自由现金流 (LFCF TTM) | 1.18 B |
| 资产报酬率 (ROA TTM) | 2.74% |
| 股东权益报酬率 (ROE TTM) | 5.23% |
新闻情绪
-
Alcon (SWX:ALC) Stock Could Be 47% Undervalued After Neurotech Acquisition
6天之前, 10:16AM
-
What Could Alcon (SWX:ALC) Q3 Sales And New Deal Mean For Growth?
6天之前, 2:17AM
-
Innovation and Product Launch Momentum Drive Alcon’s Third-Quarter 2026 Growth
10 Nov, 3:30PM
-
Alcon Inc. (ALC) Q3 2026 Earnings Call Transcript
11 Nov, 4:02PM
-
Alcon Stocks Fall 4% After Lens Implant Sales Slip and Guidance Narrows
11 Nov, 1:04PM
-
ALC's Q3 Earnings Beat, Revenues Miss, '26 Outlook Narrows, Stock Down
11 Nov, 10:37AM
AIStockmoo 评分
| 价值 30% | 2.2 |
| 来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 | NA |
| 相对其盈利增长,估值偏低。 参考 | |
| 隐含增长 参考 | NA |
| 低于其一贯估值。 参考 | |
| 负债低。盈利能力弱。短期流动性充足。现金流为正。 参考 | |
| 资本回报低于资本成本。资本回报上升。 参考 | |
| 时机 30% | 0.3 |
| 来自我们对走势图的 AI 技术分析。 参考 | NA |
| 过去一年呈下降趋势。股价略低于52周高点。 参考 | |
| 上升趋势:股价位于均线之上,均线向上。股价接近均线。 参考 | |
| K线形态 参考 | NA |
| 高于中期趋势线。 参考 | |
| 市场情绪 20% | 0.1 |
| 近期没有目标价,因此依据目标价的调整方向。 参考 | |
| 近期新闻好坏参半或中性。 参考 | |
| 聪明钱 20% | 4.9 |
| 内部交易活动 参考 | NA |
| 机构在最新13F申报中净+6.45%的股份:281家增持,334家减持(截至30 Sep 2026的季度)。 参考 | |
| 市场和行业状况中性。 | |
| 市场环境偏谨慎。 参考 | |
| 行业表现优于大市。 | |
| 各支柱方向一致,评分因此加强。 | |
| 不计入评分 | |
| 股价接近其52周平均水平。5年来下跌。 参考 | |
| 短期动能上升。 参考 | |
| 股价处于支撑位与阻力位之间。支撑与阻力水平趋升。 参考 | |
| 最终评分 | 2.21 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Instruments & Supplies (US) | 混合的 | 混合的 |
| Medical Instruments & Supplies (全球的) | 混合的 | 混合的 | |
| 股票 | Alcon Inc. | 混合的 | 看跌 |
相关股票
| 股票 | 市值 | DY | P/E(TTM) | P/B |
|---|---|---|---|---|
| ALC | - | 0.49% | - | 1.64 |
| STVN | - | 0.30% | - | 2.39 |
| RMD | - | 1.08% | - | 5.66 |
| BDX | - | 2.20% | - | 2.41 |
| WST | - | 0.37% | - | 9.67 |
| BLCO | - | - | - | 1.17 |
|
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world. |
|
| 部门 | Healthcare |
| 行业 | Medical Instruments & Supplies |
| 投资方式 | Large Growth |
| 内部持股比例 | 0.13% |
| 机构持股比例 | 68.26% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Ako Capital Llp | 30 Sep 2026 | 8,621,232 |
| Zurcher Kantonalbank (Zurich Cantonalbank) | 30 Sep 2026 | 8,013,373 |
该时间范围内无数据。
该时间范围内无数据。
机构
机构持股比例: 58.20%
| 持仓变动 | 机构数 | 股数 |
|---|---|---|
| 增持 | 281 | 45,423,731 |
| 减持 | 334 | 29,979,026 |
| 新建仓 | 87 | 20,839,836 |
| 清仓 | 88 | 5,134,527 |
来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。
| 日期 | 类型 | 细节 |
|---|---|---|
| 12 Nov 2026 | Yahoo Finance |
Are Q3 Results Altering The Investment Case For Alcon (SWX:ALC)?
Alcon reported Q3 2026 revenue of US$2.74b and net income of US$260 million, alongside a revised full year 2026 net sales growth outlook of about 6%. The business is relying more on Surgical equipment and Vision Care momentum. At the same time, U.S. premium IOL competition and slightly tighter… |
| 12 Nov 2026 | Yahoo Finance |
Alcon (SWX:ALC) Stock Could Be 47% Undervalued After Neurotech Acquisition
Alcon has delivered mixed share performance in recent years, and the question for you now is whether the current price lines up with what its cash flows can support. With fresh product approvals and an acquisition reshaping its eye care portfolio, the stock invites a closer look at what the… |
| 12 Nov 2026 | Yahoo Finance |
What Could Alcon (SWX:ALC) Q3 Sales And New Deal Mean For Growth?
Alcon (SWX:ALC) reported strong Q3 2026 sales performance, underscoring momentum in its core eye care operations. The firm received US FDA approvals for new intraocular lens products intended for use in cataract and vision correction procedures. Management broadened the portfolio with the… |
| 11 Nov 2026 | Yahoo Finance |
Alcon: 3 Key Takeaways for Long-Term Investors
Alcon's defense of its premium lens franchise against competitor trials is the test that will decide whether its growth holds up. |
| 11 Nov 2026 | Yahoo Finance |
Alcon Inc. (ALC) Q3 2026 Earnings Call Transcript
Alcon narrows 2026 guidance as its Neurotech retina deal closes. |
| 11 Nov 2026 | Yahoo Finance |
Alcon Inc (ALC) (Q3 2026) Earnings Call Highlights: Solid Sales Growth and Margin Expansion ...
Alcon Inc (ALC) delivered 5% sales growth and 15% core EPS growth in Q3 2026, driven by equipment and ocular health strength, while navigating implantable softness and narrowing full-year guidance. |
| 11 Nov 2026 | Yahoo Finance |
Alcon Stocks Fall 4% After Lens Implant Sales Slip and Guidance Narrows
U.S. competition pushed implantables down 2%, and Alcon trimmed the top of its 2026 core EPS growth range. |
| 11 Nov 2026 | Yahoo Finance |
ALC's Q3 Earnings Beat, Revenues Miss, '26 Outlook Narrows, Stock Down
Alcon's Q3 earnings top estimates as sales miss, margins expand and 2026 growth targets narrow; shares slip after the report. |
| 11 Nov 2026 | Yahoo Finance |
Alcon Inc. Q3 2026 Earnings Call Summary
Moby summary of Alcon Inc.'s Q3 2026 earnings call… |
| 10 Nov 2026 | Yahoo Finance |
Innovation and Product Launch Momentum Drive Alcon’s Third-Quarter 2026 Growth
GENEVA, November 10, 2026--Innovation and Product Launch Momentum Drive Alcon’s Third-Quarter 2026 Growth… |
| 05 Nov 2026 | Yahoo Finance |
Countdown to Alcon (ALC) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Beyond analysts' top-and-bottom-line estimates for Alcon (ALC), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2026… |
| 05 Nov 2026 | Yahoo Finance |
Alcon (ALC) Surges 6.8%: Is This an Indication of Further Gains?
Alcon (ALC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
| 04 Nov 2026 | Yahoo Finance |
Alcon Inc. (ALC) Is Positioned to Benefit From Long-Term Healthcare Demand: Here’s the Investment Case
Pershing Square Inc. recently released its Q3 2026 investor letter. A copy of the letter can be downloaded here. The letter reported 13% year-over-year growth in third-quarter fee-related earnings (FRE) to $63.7 million, while distributable earnings (DE) before taxes increased 8% to $61.0 million.… |
| 显示更多 | ||
| 股息率 (DY TTM) | 0.49% |
| 5年平均股息收益率 | 0.20% |
| 股息支付比率 | 11.81% |
| 除息日 | 公告日期 | 支付日期 | 详情 |
|---|---|---|---|
| 14 May 2024 | 08 Apr 2024 | 16 May 2024 | 0.2644 现金 |
| 10 May 2023 | 30 Mar 2023 | 12 May 2023 | 0.2356 现金 |
| 29 Apr 2022 | 24 Mar 2022 | 05 May 2022 | 0.2083 现金 |
| 04 May 2021 | 24 Mar 2021 | 06 May 2021 | 0.0909 现金 |
每年股息收益率
| 年份 | 每年总股息 ($) | 频率/年份 | 收益率 % |
|---|---|---|---|
| 2024 | 0.264 | 1 | 0.31 |
| 2023 | 0.236 | 1 | 0.30 |
| 2022 | 0.208 | 1 | 0.30 |
| 2021 | 0.091 | 1 | 0.10 |
技术形态 中期
AI 技术分析
投资组合